Company: ABBV
Filing Date: 2025-02-20
Form Type: 424B5
Source: 0001104659-25-015715
Chunk: 0

Company: AbbVie Inc.
Filing Date: 2025-02-20
Form: 424B5
Chunk 0
---
TABLE OF CONTENTS

Filed Pursuant to Rule 424(b)(5) Registration No. 333-284980 PROSPECTUS SUPPLEMENT
(To Prospectus dated February 14, 2025) $4,000,000,000 AbbVie Inc. $1,250,000,000 4.650% SENIOR NOTES DUE 2028
$1,000,000,000 4.875% SENIOR NOTES DUE 2030
$1,000,000,000 5.200% SENIOR NOTES DUE 2035
$750,000,000 5.600% SENIOR NOTES DUE 2055 Interest on each series of Notes is payable on March 15 and September 15 of each year,
commencing September 15, 2025. AbbVie Inc., a Delaware corporation (the “ Company ” or the “ Issuer ”), is offering $1,250,000,000 aggregate principal amount of its 4.650% senior notes due 2028 (the “ 2028 Notes ”), $1,000,000,000 aggregate principal amount of its 4.875% senior notes due 2030 (the “ 2030 Notes ”), $1,000,000,000 aggregate principal amount of its 5.200% senior notes due 2035 (the “ 2035 Notes ”) and $750,000,000 aggregate principal amount of its 5.600% senior notes due 2055 (the “ 2055 Notes ,” and together with the 2028 Notes, the 2030 Notes and the 2035 Notes, the “ Notes ”). Each of the 2028 Notes, the 2030 Notes, the 2035 Notes and the 2055 Notes is referred to as a “series” of Notes. The Notes will be unsecured, unsubordinated obligations of the Company and will rank equally in right of payment with all of the Company’s existing and future unsecured, unsubordinated indebtedness, liabilities and other obligations. The Notes will be issued in minimum denominations of $2,000 and in integral multiples of $1,000 in excess thereof. The Notes will not be listed on any securities exchange. Currently there is no public market for any series of the Notes. The Company expects the net proceeds to it from this offering will be approximately $3.97 billion (after deducting underwriting discounts and its estimated offering expenses